Youn H Kim

Publications

• In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R. Blood. 2012; 119 (2): 355-63
• Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma. Bashey S, Krathen M, Abdulla F, Sundram U, Kim YH. J Clin Oncol. 2012; 30 (24): e221-5
• Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Lee CS, Ungewickell A, Bhaduri A, Qu K, Webster DE, Armstrong R, Weng WK, Aros CJ, Mah A, Chen RO, Lin M, Sundram U, Chang HY, Kretz M, Kim YH, Khavari PA. Blood. 2012; 120 (16): 3288-97
• Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, Hoppe R. Int J Radiat Oncol Biol Phys. 2011; 81 (4): e651-7
• Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. J Clin Oncol. 2010; 28 (29): 4485-91
• In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. J Clin Oncol. 2010; 28 (28): 4324-32
• Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, Hoppe RT, Kim YH. Arch Dermatol. 2009; 145 (6): 667-74
• Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ. Blood. 2007; 109 (11): 4655-62
• TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT. Blood. 2007; 110 (2): 479-84
• Clonal identity and differences in primary cutaneous B-cell lymphoma occurring at different sites or time points in the same patient. Fujiwara M, Morales AV, Seo K, Kim YH, Arber DA, Sundram UN. Am J Dermatopathol. 2013; 35 (1): 11-8
• Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity. Metcalf RA, Bashey S, Wysong A, Kim J, Kim YH, Gratzinger D. Am J Surg Pathol. 2013; 37 (4): 617-23
• A comparative analysis of cutaneous marginal zone lymphoma and cutaneous chronic lymphocytic leukemia. Levin C, Mirzamani N, Zwerner J, Kim Y, Schwartz EJ, Sundram U. Am J Dermatopathol. 2012; 34 (1): 18-23
• Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Guitart J, Weisenburger DD, Subtil A, Kim E, Wood G, Duvic M, Olsen E, Junkins-Hopkins J, Rosen S, Sundram U, Ivan D, Selim MA, Pincus L, Deonizio JM, Kwasny M, Kim YH. Am J Surg Pathol. 2012; 36 (11): 1656-65
• Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. J Clin Oncol. 2011; 29 (18): 2598-607
• The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Navi D, Riaz N, Levin YS, Sullivan NC, Kim YH, Hoppe RT. Arch Dermatol. 2011; 147 (5): 561-7
• The frequency of dual TCR-PCR clonality in granulomatous disorders. Dabiri S, Morales A, Ma L, Sundram U, Kim YH, Arber DA, Kim J. J Cutan Pathol. 2011; 38 (9): 704-9
• Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. Zhang B, Beck AH, Taube JM, Kohler S, Seo K, Zwerner J, Viakhereva N, Sundram U, Kim YH, Schrijver I, Arber DA, Zehnder JL. J Mol Diagn. 2010; 12 (3): 320-7
• Multidisciplinary care in the management of patients with cutaneous lymphoma: a perspective. Kim YH, Clin Lymphoma Myeloma Leuk. 2010: 10 S106-8
• Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. J Am Acad Dermatol. 2010; 63 (6): 975-83
• A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. Clin Cancer Res. 2009; 15 (19): 6217-24
• Cutaneous peripheral T-cell lymphoma associated with a proliferation of B cells. Mattoch IW, Fulton R, Kim Y, Hoppe R, Warnke RA, Sundram UN. Am J Clin Pathol. 2009; 131 (6): 810-9
• Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Weinberg OK, Ma L, Seo K, Beck AH, Pai RK, Morales A, Kim Y, Sundram U, Tan D, Horning SJ, Hoppe RT, Natkunam Y, Arber DA. Am J Surg Pathol. 2009; 33 (4): 591-8
• Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease. Lee J, Viakhireva N, Cesca C, Lee P, Kohler S, Hoppe RT, Kim YH. J Am Acad Dermatol. 2008; 59 (4): 706-12
• Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies. Pai RK, Mullins FM, Kim YH, Kong CS. Cancer. 2008; 114 (5): 323-32
• Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. Morales AV, Arber DA, Seo K, Kohler S, Kim YH, Sundram UN. Am J Dermatopathol. 2008; 30 (5): 425-30
• Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH. J Am Acad Dermatol. 2008; 59 (6): 953-7
• Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Richmond H, Zwerner J, Kim Y, Fiorentino D. Arch Dermatol. 2007; 143 (8): 1025-30
• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. J Clin Oncol. 2007; 25 (21): 3109-15
• Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Huang KP, Weinstock MA, Clarke CA, McMillan A, Hoppe RT, Kim YH. Arch Dermatol. 2007; 143 (1): 45-50
• T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. Thurber SE, Zhang B, Kim YH, Schrijver I, Zehnder J, Kohler S. J Am Acad Dermatol. 2007; 57 (5): 782-90
• Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. Jayaraman AG, Cassarino D, Advani R, Kim YH, Tsai E, Kohler S. J Cutan Pathol. 2006: 33 Suppl 2 6-11
• Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, Chow S, Advani R, Warnke R, Kohler S, Hoppe RT, Kim YH. Arch Dermatol. 2006; 142 (5): 577-84
• Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. J Cutan Pathol. 2005; 32 (3): 227-34
• Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. Beynet DP, Wee SA, Horwitz SS, Kohler S, Horning S, Hoppe R, Kim YH. Arch Dermatol. 2004; 140 (9): 1140-6
• CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. J Am Acad Dermatol. 2003; 49 (6): 1049-58
• Gene expression profiles of cutaneous B cell lymphoma. Storz MN, van de Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, Kohler S. J Invest Dermatol. 2003; 120 (5): 865-70
• Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Arch Dermatol. 2003; 139 (7): 857-66
• Management with topical nitrogen mustard in mycosis fungoides. Kim YH, Dermatol Ther. 2003; 16 (4): 288-98
• Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Kim YH, Martinez G, Varghese A, Hoppe RT. Arch Dermatol. 2003; 139 (2): 165-73
• Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases. Harvell J, Vaseghi M, Natkunam Y, Kohler S, Kim Y. J Cutan Pathol. 2002; 29 (2): 88-92
• Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. de Coninck EC, Kim YH, Varghese A, Hoppe RT. J Clin Oncol. 2001; 19 (3): 779-84
• Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. Mraz-Gernhard S, Natkunam Y, Hoppe RT, LeBoit P, Kohler S, Kim YH. J Clin Oncol. 2001; 19 (8): 2179-88
• Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. Natkunam Y, Warnke RA, Haghighi B, Su LD, Le Boit PE, Kim YH, Kohler S. J Cutan Pathol. 2000; 27 (8): 392-9
• Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Kim YH, Chow S, Varghese A, Hoppe RT. Arch Dermatol. 1999; 135 (1): 26-32
• Epidermotropic cutaneous B-cell lymphoma mimicking mycosis fungoides. Chui CT, Hoppe RT, Kohler S, Kim YH. J Am Acad Dermatol. 1999; 41 (2 Pt 1): 271-4
• Mycosis fungoides and the Sézary syndrome. Kim YH, Hoppe RT. Semin Oncol. 1999; 26 (3): 276-89
• Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Chinn DM, Chow S, Kim YH, Hoppe RT. Int J Radiat Oncol Biol Phys. 1999; 43 (5): 951-8
• Mycosis fungoides in young patients: clinical characteristics and outcome. Crowley JJ, Nikko A, Varghese A, Hoppe RT, Kim YH. J Am Acad Dermatol. 1998; 38 (5 Pt 1): 696-701
• Role of histology in providing prognostic information in mycosis fungoides. Smoller BR, Detwiler SP, Kohler S, Hoppe RT, Kim YH. J Cutan Pathol. 1998; 25 (6): 311-5
• Blastomycosis-like pyoderma in a man with AIDS. Crowley JJ, Kim YH. J Am Acad Dermatol. 1997; 36 (4): 633-4
• Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sézary syndrome: a critical reappraisal. Kohler S, Kim YH, Smoller BR. J Cutan Pathol. 1997; 24 (5): 292-7
• Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Arch Dermatol. 1996; 132 (11): 1309-13
• Cutaneous gnathostomiasis. Crowley JJ, Kim YH. J Am Acad Dermatol. 1995; 33 (5 Pt 1): 825-8
• Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Kim YH, Bishop K, Varghese A, Hoppe RT. Arch Dermatol. 1995; 131 (9): 1003-8
• Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Smoller BR, Bishop K, Glusac E, Kim YH, Hendrickson M. Am J Surg Pathol. 1995; 19 (12): 1423-30
• Autoimmunity to anchoring fibrils. Kim YH, Woodley DT. Adv Dermatol. 1994: 9 61-77; discussion 78
• Constitutive activation of the collagenase promoter in recessive dystrophic epidermolysis bullosa fibroblasts: role of endogenously activated AP-1. Unemori EN, Mauch C, Hoeffler W, Kim Y, Amento EP, Bauer EA. Exp Cell Res. 1994; 211 (2): 212-8
• A double-blind comparison of adhesive bandages with the use of uniform suction blister wounds. Woodley DT, Kim YH. Arch Dermatol. 1992; 128 (10): 1354-7
• Recessive dystrophic epidermolysis bullosa phenotype is preserved in xenografts using SCID mice: development of an experimental in vivo model. Kim YH, Woodley DT, Wynn KC, Giomi W, Bauer EA. J Invest Dermatol. 1992; 98 (2): 191-7
• 1H NMR spectroscopy: an approach to evaluation of diseased skin in vivo. Kim YH, Orenberg EK, Faull KF, Wade-Jardetzky NG, Jardetzky O. J Invest Dermatol. 1989; 92 (2): 210-6